- Home
- WALD vs NBP Comparison
WALD vs NBP Comparison
Compare WALD & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WALD | NBP |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.3M | 205.9M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WALD | NBP |
|---|---|---|
| Price | $1.33 | $1.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $2.00 | ★ $9.00 |
| AVG Volume (30 Days) | 159.2K | ★ 253.2K |
| Earning Date | 03-13-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.89 | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $1.46 |
| 52 Week High | $3.22 | $5.19 |
Technical Indicators
Market Signals| Indicator | WALD | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 45.05 | 40.86 |
| Support Level | $1.24 | $1.67 |
| Resistance Level | $1.83 | $1.98 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 45.24 | 2.94 |
Price Performance
Historical ComparisonAbout WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.